Key facts
- This page summarizes Jeffrey Eisele's Form 4 filing for Apellis Pharmaceuticals, Inc. (APLS).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 23 Dec 2022, 15:15.
Jeffrey Eisele - 25 Apr 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)
- Reporting relationship
- Exec VP, Program Team Lead
- Issuer ticker
- APLS
- Reported as of
- 25 Apr 2022
- Net transaction value
- -$4,600
- SEC form
- 4
- Accepted by SEC
- 23 Dec 2022, 15:15:35 UTC
- Prior SEC filing
- 01 Feb 2022
- Next SEC filing
- 17 Jan 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ David Watson, attorney-in-fact for Jeffrey Eisele
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jeffrey Eisele filed Form 4 for Apellis Pharmaceuticals, Inc. (APLS) on 23 Dec 2022.
Change
- Previous filing in this sequence was filed on 01 Feb 2022.
- Current net transaction value: -$4,600.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
APLS
transaction
Common Stock
Other
- Transaction value
- $0
- Shares
- -1,250
- Change %
- -3.8%
- Price
- $0.000000
- Shares after
- 31,739
- Date
- 25 Apr 2022
- Ownership
- Direct
- Footnotes
- F1
APLS
transaction
Common Stock
Tax liability
- Transaction value
- $4,600
- Shares
- -89
- Change %
- -0.28%
- Price
- $51.68
- Shares after
- 31,650
- Date
- 22 Dec 2022
- Ownership
- Direct
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
This represents the cancellation of a PSU awards granted on 01/28/2021 that was originally reported in table I upon grant. The performance metrics were not met.
Footnote F2
This represents shares used to cover tax withholding on a Restricted Stock Unit release.